Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

For best results when printing this announcement, please click on link below: Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026 Operational launch of InVimmune, a subsidiary dedicated to differentiated approaches to in vivo cell therapy, with a first indication announced in oncology. Appointment of Gilles Besin as Chief Executive Officer, effective( )July 2026. Signing of a binding term sheet with Abivax with a view to an exclusive global collaboration. Achievement of a major strategic milestone with the acquisition of Etherna Immunotherapies NV; the transaction is expected to be finalised on 8 October 2026. Cash and cash equivalents totaling €656,000 as at 30 June 2026. As of the date of the half-year financier report, the cash position covers 12 months. Regulatory News: Valerio Therapeutics (FR0010095596 — ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results.